These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 21058106)

  • 1. Introduction to discussion papers on draft FDA guidance on adaptive designs.
    Chang M
    J Biopharm Stat; 2010 Nov; 20(6):1113-4. PubMed ID: 21058106
    [No Abstract]   [Full Text] [Related]  

  • 2. Comments on the FDA draft guidance on adaptive designs.
    Wittes J
    J Biopharm Stat; 2010 Nov; 20(6):1166-70. PubMed ID: 21058112
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA draft guidance on adaptive design clinical trials: Pfizer's perspective.
    Chuang-Stein C; Beltangady M
    J Biopharm Stat; 2010 Nov; 20(6):1143-9. PubMed ID: 21058110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On flexibility of adaptive designs and criteria for choosing a good one--a discussion of FDA draft guidance.
    Cheng B; Chow SC
    J Biopharm Stat; 2010 Nov; 20(6):1171-7. PubMed ID: 21058113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group.
    Gallo P; Anderson K; Chuang-Stein C; Dragalin V; Gaydos B; Krams M; Pinheiro J
    J Biopharm Stat; 2010 Nov; 20(6):1115-24. PubMed ID: 21058107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A note on special articles on adaptive clinical trial designs.
    Chow SC
    J Biopharm Stat; 2010 Nov; 20(6):1088-9. PubMed ID: 21058103
    [No Abstract]   [Full Text] [Related]  

  • 7. Editorial: Adaptive designs: appealing in development of therapeutics, and where do controversies lie?
    Wang SJ
    J Biopharm Stat; 2010 Nov; 20(6):1083-7. PubMed ID: 21058102
    [No Abstract]   [Full Text] [Related]  

  • 8. Review of draft FDA adaptive design guidance.
    Cook T; DeMets DL
    J Biopharm Stat; 2010 Nov; 20(6):1132-42. PubMed ID: 21058109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the FDA guidance on adaptive designs: historical, legal, and statistical perspectives.
    Liu Q; Chi GY
    J Biopharm Stat; 2010 Nov; 20(6):1178-219. PubMed ID: 21058114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive methods: telling "the rest of the story".
    Emerson SS; Fleming TR
    J Biopharm Stat; 2010 Nov; 20(6):1150-65. PubMed ID: 21058111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Note on special technical issue on adaptive designs for clinical trials.
    Liu Q; Chang M
    J Biopharm Stat; 2012; 22(4):615-6. PubMed ID: 22651104
    [No Abstract]   [Full Text] [Related]  

  • 12. Comments on the draft guidance on "adaptive design clinical trials for drugs and biologics" of the U.S. Food and Drug Administration.
    Brannath W; Burger HU; Glimm E; Stallard N; Vandemeulebroecke M; Wassmer G
    J Biopharm Stat; 2010 Nov; 20(6):1125-31. PubMed ID: 21058108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives on the use of adaptive designs in clinical trials. Part II. Panel discussion.
    Benda N; Brannath W; Bretz F; Burger HU; Friede T; Maurer W; Wang SJ
    J Biopharm Stat; 2010 Nov; 20(6):1098-112. PubMed ID: 21058105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives on the use of adaptive designs in clinical trials. Part I. Statistical considerations and issues.
    Wang SJ
    J Biopharm Stat; 2010 Nov; 20(6):1090-7. PubMed ID: 21058104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency.
    Bottomley A; Jones D; Claassens L
    Eur J Cancer; 2009 Feb; 45(3):347-53. PubMed ID: 19013787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress report on the guidance for industry for statistical aspects of the design, analysis, and interpretation of chronic rodent carcinogenicity studies of pharmaceuticals.
    Lin KK
    J Biopharm Stat; 2000 Nov; 10(4):481-501. PubMed ID: 11104389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working Group.
    Gallo P; Chuang-Stein C; Dragalin V; Gaydos B; Krams M; Pinheiro J;
    J Biopharm Stat; 2006 May; 16(3):275-83; discussion 285-91, 293-8, 311-2. PubMed ID: 16724485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discussion of the paper "Adaptive dose-ranging designs".
    Burman CF
    J Biopharm Stat; 2007; 17(6):1005-11; discussion 1029-32. PubMed ID: 18027210
    [No Abstract]   [Full Text] [Related]  

  • 19. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
    Heemstra HE; Leufkens HG; Rodgers RP; Xu K; Voordouw BC; Braun MM
    Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adaptive designs in clinical drug development: opportunities, challenges, and scope reflections following PhRMA's November 2006 workshop.
    Krams M; Burman CF; Dragalin V; Gaydos B; Grieve AP; Pinheiro J; Maurer W; Gallo P
    J Biopharm Stat; 2007; 17(6):957-64. PubMed ID: 18027207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.